Xtant Medical Holdings (XTNT) AI Stock Analysis

• Market Cap: $82.67M
• Dividend Yield: N/A
• Average Volume (3M): 324.37K
• Price to Earnings (P/E): 57.8
• Beta (1Y): 1.19
• Revenue Growth: 16.88%
• EPS Growth: N/A
• Country: US
• Employees: 217
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): <0.01
• Shares Outstanding: 140,004,240
• 10 Day Avg. Volume: 155,748
• 30 Day Avg. Volume: 324,372
• PEG Ratio: <0.01
• Price to Book (P/B): 1.38
• Price to Sales (P/S): 0.50
• P/FCF Ratio: -3.70
• Enterprise Value/Market Cap: 1.44
• Enterprise Value/Revenue: 0.90
• Enterprise Value/Gross Profit: 1.45
• Enterprise Value/Ebitda: 10.96
• 1Y Price Target: $1.50
• Price Target Upside: 141.94% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.03
• Revenue Forecast (FY): $133.30M

• Rating: 59 Neutral
• Price Target: $0.62 ▼(-0.48% Downside)

Xtant Medical Holdings is on a recovery path with strong revenue growth and improving financial metrics. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The positive outlook from the earnings call, including strategic initiatives and asset sales, supports future growth prospects.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Xtant's products and successful market penetration, supporting long-term business expansion.

Improved Gross Margin

Improved gross margins reflect better cost management and product mix, enhancing profitability and financial health over the long term.

Pending Asset Sale

The asset sale will reduce debt and improve liquidity, allowing Xtant to focus on core operations and invest in growth opportunities.

Negative Factors

Decline in Hardware Revenue

Declining hardware revenue suggests challenges in this segment, potentially impacting overall revenue growth and market competitiveness.

Challenges in Biologics Growth

Slower biologics growth indicates potential market saturation or competitive pressures, affecting future revenue and strategic goals.

Cost-Cutting Measures

Cost-cutting may indicate financial strain or inefficiencies, potentially impacting employee morale and long-term operational capabilities.

Xtant Medical Holdings Business Overview & Revenue Model

Company Description

Xtant Medical Holdings (XTNT) is a medical technology company focused on developing and commercializing innovative solutions for the orthopedic and spinal surgery markets. The company specializes in regenerative medicine, offering a range of products including allograft tissue, spinal implants, and orthopedic surgical instruments designed to enhance patient outcomes and improve surgical efficiency. Xtant Medical operates primarily in the sectors of bone grafting and spinal surgery, positioning itself as a key player in the growing field of regenerative solutions.

How the Company Makes Money

Xtant Medical generates revenue primarily through the sale of its surgical products and devices, which include allografts, spinal implants, and orthopedic instrumentation. The company’s revenue model is built on a combination of direct sales to hospitals and surgical centers, as well as partnerships with distributors and medical device companies that expand their market reach. Key revenue streams include the sales of their proprietary allograft products, which are essential for various surgical procedures, and recurring sales from spinal implant systems. Additionally, Xtant Medical benefits from collaborations with healthcare providers and research organizations that enhance its product offerings and market presence, contributing positively to its earnings.

Xtant Medical Holdings Financial Statement Overview

Summary

Xtant Medical Holdings is showing signs of recovery with improving revenue and operational metrics. The balance sheet is strengthening with reduced leverage, but profitability and cash flow generation remain areas of concern. Continued focus on cost management and cash flow improvement will be crucial for sustained financial health.

Income Statement

Xtant Medical Holdings has shown a positive trend in revenue growth, with a TTM revenue increase of 4.16%. The gross profit margin is strong at 60.16% for TTM, indicating efficient cost management. However, the net profit margin remains negative, albeit improving, reflecting ongoing challenges in achieving profitability. The EBIT and EBITDA margins have turned positive in TTM, suggesting operational improvements.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.31 in TTM, indicating a healthier balance sheet with reduced leverage. The return on equity is still negative, but the trajectory shows improvement. The equity ratio is stable, suggesting a solid capital structure. Overall, the balance sheet reflects a strengthening financial position.

Cash Flow

Cash flow from operations has turned positive in TTM, a significant improvement from previous periods. However, free cash flow growth is negative, highlighting challenges in generating cash after capital expenditures. The operating cash flow to net income ratio is low, indicating limited cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	133.08M	117.27M	91.30M	57.97M	55.26M	53.34M
Gross Profit	82.54M	68.22M	55.47M	32.14M	32.49M	34.39M
EBITDA	10.90M	-7.88M	5.08M	-5.43M	-2.51M	1.33M
Net Income	1.75M	-16.45M	660.00K	-8.48M	-4.85M	-7.02M
Balance Sheet
Total Assets	106.32M	93.84M	92.61M	60.23M	54.69M	41.47M
Cash, Cash Equivalents and Short-Term Investments	10.40M	6.20M	5.71M	20.30M	18.24M	2.34M
Total Debt	15.08M	35.14M	23.56M	17.07M	16.84M	18.54M
Total Liabilities	55.94M	50.87M	41.26M	26.06M	23.81M	26.95M
Stockholders Equity	50.38M	42.96M	51.35M	34.17M	30.88M	14.51M
Cash Flow
Free Cash Flow	5.17M	-16.01M	-10.97M	-7.11M	-1.68M	-2.28M
Operating Cash Flow	7.83M	-11.90M	-9.52M	-5.34M	439.00K	-731.00K
Investing Cash Flow	2.65M	-3.73M	-24.78M	-1.56M	-1.89M	-1.30M
Financing Cash Flow	-6.88M	16.07M	19.69M	9.02M	17.50M	-861.00K

Xtant Medical Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTNT, the sentiment is Negative. The current price of 0.62 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.71, and above the 200-day MA of 0.61, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 36.09 is Neutral, neither overbought nor oversold. The STOCH value of 24.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XTNT.

Xtant Medical Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APYX	60 Neutral	$166.93M	―	-172.18%	―	-1.32%	55.62%
XTNT	59 Neutral	$82.67M	57.84	3.64%	―	16.88%	―
FONR	59 Neutral	$89.73M	12.85	4.34%	―	3.36%	-21.15%
NVNO	58 Neutral	$13.14M	-0.57	-57.19%	―	―	18.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VANI	44 Neutral	$104.22M	-3.41	-265.02%	―	―	-0.27%
TELA	38 Underperform	$51.11M	-1.15	―	―	12.24%	47.45%

Xtant Medical Holdings Corporate Events

Xtant Medical Reports Strong Q3 2025 Results

Xtant Medical Holdings Inc. is a global medical technology company specializing in surgical solutions for spinal and orthopedic conditions, with a focus on orthobiologics and spinal implant systems.

Xtant Medical Holdings’ Earnings Call: Positive Growth Amid Challenges

Xtant Medical Holdings Inc. recently held its earnings call, presenting a generally positive outlook despite some challenges. The company reported strong revenue growth, improved margins, and successful new product launches, although it faces hurdles in hardware revenue and slower than expected growth in its biologics product family. The anticipated asset sale is expected to bolster the company’s financial standing further.

Xtant Medical Approves Equity Plan Amendment at Meeting

On November 7, 2025, Xtant Medical Holdings held its annual stockholders meeting, where an amendment to the 2023 Equity Incentive Plan was approved, increasing the number of shares by 12,300,000. This decision, alongside other proposals such as the election of directors and the ratification of Grant Thornton LLP as the accounting firm, reflects the company’s strategic moves to enhance its operational framework and shareholder engagement.

The most recent analyst rating on (XTNT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.

Xtant Medical’s Earnings Call Highlights Growth and Challenges

Xtant Medical Holdings Inc. recently held its earnings call, revealing a generally positive sentiment with notable revenue growth driven by the biologics segment. The company showcased improved margins and successful product launches, although challenges persist in the hardware segment and licensing revenue remains uncertain.

Xtant Medical Reports Strong Q2 2025 Results

Xtant Medical Holdings Inc. is a global medical technology company specializing in surgical solutions for spinal, orthopedic, and wound care disorders, focusing on the development and commercialization of orthobiologics and spinal implant systems.

Xtant Medical Reports Strong Q2 2025 Financial Results

On August 12, 2025, Xtant Medical Holdings announced its second quarter 2025 financial results, reporting a total revenue of $35.4 million, an 18% increase year-over-year. The company achieved a positive net income of $3.6 million compared to a net loss in the previous year and raised its full-year 2025 revenue guidance to $131-$135 million, reflecting an 11%-15% growth over 2024. Xtant Medical also highlighted its strategic move to sell non-core spinal implant and OUS businesses to Companion Spine for approximately $19.2 million, aiming to strengthen its balance sheet and focus on its core biologics business. The launch of OsteoFactor Pro™ and Trivium™ products further positions Xtant as a leader in orthobiologic solutions, enhancing its market presence and value for shareholders.

The most recent analyst rating on (XTNT) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Xtant Medical Holdings stock, see the XTNT Stock Forecast page.